APGE
Apogee Therapeutics, Inc.
Next earnings Aug 10, 2026 · consensus $-1.10 EPS
Last earnings +1.9% on 2026-05-11
$132.55
▼ -0.10%$132.55▲ +220.56%
over 1Y
L $34.65EODHDH $132.88
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.1%
1W+0.0%
1M+70.5%
3M+70.3%
YTD+74.9%
1Y+220.6%
Hold
Conviction
Horizon
Long (>12mo)
Street · 25 analysts
Buy
Well-funded clinical-stage biotech (~$903M liquidity) but pre-revenue and burning $227M/yr — a binary, catalyst-driven bet on zumilokibart.
Net income -$256M · FY2025
Apogee Therapeutics is a clinical-stage biotech developing antibody therapies for inflammatory and immunology indications, led by zumilokibart (APG777) plus APG279, APG273 and APG808. It has no product revenue and no approved products, so the investment case rests entirely on pipeline progress rather than current financials. FY2025 reflects a company in full development mode: net loss widened to -$256M, operating loss to -$286M, and R&D rose 27.9% to $215M as trials advanced. Operating cash burn was -$227M.
Financials · annual, by fiscal year
| Line item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$30.7M | -$93.0M | -$217M | -$286M |
| Net income | -$39.8M | -$84.0M | -$182M | -$256M |
| Diluted EPS | -$16.16 | -$3.36 | -$3.30 | -$4.22 |
| Net margin | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value—
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow-$233M
Total debt—
Net cash$132M
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗DEFA14AFiling2026-06-26open ↗4Period ending 2026-06-222026-06-24open ↗4Period ending 2026-06-222026-06-24open ↗SCHEDULE 13D/AFiling2026-06-23open ↗DEFA14AFiling2026-06-22open ↗144Filing2026-06-22open ↗144Filing2026-06-22open ↗DEFA14AFiling2026-06-22open ↗8-KPeriod ending 2026-06-182026-06-22open ↗8-KPeriod ending 2026-06-172026-06-22open ↗4Period ending 2026-06-102026-06-12open ↗8-KPeriod ending 2026-06-092026-06-12open ↗
Frequently asked
- Is Apogee Therapeutics, Inc. (APGE) a buy?
- APGE currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Well-funded clinical-stage biotech (~$903M liquidity) but pre-revenue and burning $227M/yr — a binary, catalyst-driven bet on zumilokibart.
- What is Apogee Therapeutics, Inc.'s quality score?
- APGE scores 23.999999999999996/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001974640, latest 10-Q filed 2026-05-11) · EODHD · analysis by claude-code · as of 6/21/2026, 8:55:55 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.